Pamidran (Pamidronate Disodium)

Pamidronate disodium, the active ingredient in Pamidran, is a bisphosphonate presented as a sterile injectable solution for intravenous use. It is employed in the management of bone‑related disorders, particularly in patients with elevated bone turnover such as those with malignancy‑associated hypercalcaemia.

GNH USA supplies Pamidran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidran is a bisphosphonate that acts on disorders of calcium and bone metabolism: - Hypercalcaemia of malignancy: reduces the elevated serum calcium levels. - Bone metastases associated with solid tumours and multiple myeloma – helps prevent skeletal‑related events. - Osteolysis after solid organ transplant or renal failure – slows progress of bone loss. - Paget of the circuit ?  ??  ---   ???